1887

Abstract

Little is known about the potential effects of insertions and deletions (indels) on the evolutionary dynamics of hepatitis C virus (HCV). In fact, the consequences of indels on antiviral treatment response are a field of investigation completely unexplored. Here, an extensive sequencing project was undertaken by cloning and sequencing serum samples from 25 patients infected with HCV subtype 1a and 48 patients with subtype 1b. For 23 patients, samples obtained after treatment with alpha interferon plus ribavirin were also available. Two genome fragments containing the hypervariable regions in the envelope 2 glycoprotein and the PKR-BD domain in NS5A were sequenced, yielding almost 16 000 sequences. Our results show that insertions are quite rare, but they are often present in biologically relevant domains of the HCV genome. Moreover, their frequency distributions between different time samples reflect the quasispecies dynamics of HCV populations. Deletions seem to be subject to negative selection.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.82855-0
2007-08-01
2019-10-17
Loading full text...

Full text loading...

/deliver/fulltext/jgv/88/8/2198.html?itemId=/content/journal/jgv/10.1099/vir.0.82855-0&mimeType=html&fmt=ahah

References

  1. Abe, K., Inchauspe, G. & Fujisawa, K. ( 1992; ). Genomic characterization and mutation rate of hepatitis C virus isolated from a patient who contracted hepatitis during an epidemic of non-A, non-B hepatitis in Japan. J Gen Virol 73, 2725–2729.[CrossRef]
    [Google Scholar]
  2. Afdhal, N. H. ( 2004; ). The natural history of hepatitis C. Semin Liver Dis 24 (Suppl. 2), 3–8.
    [Google Scholar]
  3. Akuta, N., Suzuki, F., Kawamura, Y., Yatsuji, H., Sezaki, H., Suzuki, Y., Hosaka, T., Kobayashi, M., Kobayashi, M. & other authors ( 2007; ). Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 46, 403–410.[CrossRef]
    [Google Scholar]
  4. Bracho, M. A., García-Robles, I., Jiménez, N., Torres-Puente, M., Moya, A. & González-Candelas, F. ( 2004; ). Effect of oligonucleotide primers in determining viral variability within hosts. Virol J 1, 13 [CrossRef]
    [Google Scholar]
  5. Brillanti, S., Garson, J., Foli, M., Whitby, K., Deaville, R., Masci, C., Miglioli, M. & Barbara, L. ( 1994; ). A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 107, 812–817.[CrossRef]
    [Google Scholar]
  6. Casino, C., McAllister, J., Davidson, F., Power, J., Lawlor, E., Yap, P. L., Simmonds, P. & Smith, D. B. ( 1999; ). Variation of hepatitis C virus following serial transmission: multiple mechanisms of diversification of the hypervariable region and evidence for convergent genome evolution. J Gen Virol 80, 717–725.
    [Google Scholar]
  7. Castelain, S., Bonte, D., Penin, F., Francois, C., Capron, D., Dedeurwaerder, S., Zawadzki, P., Morel, V., Wychowski, C. & Duverlie, G. ( 2007; ). Hepatitis C virus p7 membrane protein quasispecies variability in chronically infected patients treated with interferon and ribavirin, with or without amantadine. J Med Virol 79, 144–154.[CrossRef]
    [Google Scholar]
  8. Chamberlain, R. W., Adams, N. J., Taylor, L. A., Simmonds, P. & Elliott, R. M. ( 1997; ). The complete coding sequence of hepatitis C virus genotype 5a, the predominant genotype in South Africa. Biochem Biophys Res Commun 236, 44–49.[CrossRef]
    [Google Scholar]
  9. Curran, R., Jameson, C. L., Craggs, J. K., Grabowska, A. M., Thomson, B. J., Robins, A., Irving, W. L. & Ball, J. K. ( 2002; ). Evolutionary trends of the first hypervariable region of the hepatitis C virus E2 protein in individuals with differing liver disease severity. J Gen Virol 83, 11–23.
    [Google Scholar]
  10. Dienstag, J. L. & McHutchison, J. G. ( 2006; ). American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 130, 231–264.[CrossRef]
    [Google Scholar]
  11. Durante Mangoni, E., Forton, D. M., Ruggiero, G. & Karayiannis, P. ( 2003; ). Hepatitis C virus E2 and NS5A region variability during sequential treatment with two interferon-α preparations. J Med Virol 70, 62–73.[CrossRef]
    [Google Scholar]
  12. Duverlie, G., Khorsi, H., Castelain, S., Jaillon, O., Izopet, J., Lunel, F., Eb, F., Penin, F. & Wychowski, C. ( 1998; ). Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. J Gen Virol 79, 1373–1381.
    [Google Scholar]
  13. Eigen, M. & Biebricher, C. K. ( 1988; ). Sequence space and quasispecies distribution. In Variability of RNA Genomes, pp. 211–245. Edited by E. Domingo, J. J. Holland & P. Ahlquist. Boca Raton, FL: CRC Press.
  14. Enomoto, N., Sakuma, I., Asahina, Y., Kurosaki, M., Murakami, T., Yamamoto, C., Ogura, Y., Izumi, N., Marumo, F. & Sato, C. ( 1996; ). Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334, 77–81.[CrossRef]
    [Google Scholar]
  15. Farci, P., Shimoda, A., Coiana, A., Diaz, G., Peddis, G., Melpolder, J. C., Strazzera, A., Chien, D. Y., Munoz, S. J. & other authors ( 2000; ). The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288, 339–344.[CrossRef]
    [Google Scholar]
  16. Farci, P., Strazzera, R., Alter, H. J., Farci, S., Degioannis, D., Coiana, A., Peddis, G., Usai, F., Serra, G. & other authors ( 2002; ). Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci U S A 99, 3081–3086.[CrossRef]
    [Google Scholar]
  17. Farci, P., Quinti, I., Farci, S., Alter, H. J., Strazzera, R., Palomba, E., Coiana, A., Cao, D., Casadei, A. M. & other authors ( 2006; ). Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively. Proc Natl Acad Sci U S A 103, 8475–8480.[CrossRef]
    [Google Scholar]
  18. Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Goncales, F. L., Jr, Haussinger, D., Diago, M., Carosi, G. & other authors ( 2002; ). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347, 975–982.[CrossRef]
    [Google Scholar]
  19. Gale, M. J., Jr, Korth, M. J., Tang, N. M., Tan, S. L., Hopkins, D. A., Dever, T. E., Polyak, S. J., Gretch, D. R. & Katze, M. G. ( 1997; ). Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230, 217–227.[CrossRef]
    [Google Scholar]
  20. Gale, M. J., Jr, Korth, M. J. & Katze, M. G. ( 1998; ). Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: a potential mechanism of interferon resistance. Clin Diagn Virol 10, 157–162.[CrossRef]
    [Google Scholar]
  21. Gerotto, M., Dal Pero, F., Loffreda, S., Bianchi, F. B., Alberti, A. & Lenzi, M. ( 2001; ). A 385 insertion in the hypervariable region 1 of hepatitis C virus E2 envelope protein is found in some patients with mixed cryoglobulinemia type 2. Blood 98, 2657–2663.[CrossRef]
    [Google Scholar]
  22. Heathcote, J. & Main, J. ( 2005; ). Treatment of hepatitis C. J Viral Hepat 12, 223–235.[CrossRef]
    [Google Scholar]
  23. Hohne, M., Schreier, E. & Roggendorf, M. ( 1994; ). Sequence variability in the env-coding region of hepatitis C virus isolated from patients infected during a single source outbreak. Arch Virol 137, 25–34.[CrossRef]
    [Google Scholar]
  24. Hoofnagle, J. H., Mullen, K. D., Jones, D. B., Rustgi, V., Di Bisceglie, A., Peters, M., Waggoner, J. G., Park, Y. & Jones, E. A. ( 1986; ). Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 315, 1575–1578.[CrossRef]
    [Google Scholar]
  25. Jiménez-Hernández, N., Torres-Puente, M., Bracho, M. A., García-Robles, I., Ortega, E., del Olmo, J., Carnicer, F., González-Candelas, F. & Moya, A. ( 2007; ). Epidemic dynamics of two coexisting hepatitis C virus subtypes. J Gen Virol 88, 123–133.[CrossRef]
    [Google Scholar]
  26. Kato, N., Ootsuyama, Y., Tanaka, T., Nakagawa, M., Nakazawa, T., Muraiso, K., Ohkoshi, S., Hijikata, M. & Shimotohno, K. ( 1992; ). Marked sequence diversity in the putative envelope proteins of hepatitis C viruses. Virus Res 22, 107–123.[CrossRef]
    [Google Scholar]
  27. Kuiken, C., Combet, C., Bukh, J., Shin-i, T., Deleage, G., Mizokami, M., Richardson, R. L., Sablon, E., Yusim, K. & other authors ( 2006; ). A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes. Hepatology 44, 1355–1361.[CrossRef]
    [Google Scholar]
  28. Lindenbach, B. D. & Rice, C. M. ( 2005; ). Unravelling hepatitis C virus replication from genome to function. Nature 436, 933–938.[CrossRef]
    [Google Scholar]
  29. Liu, S., Ansari, I. H., Das, S. C. & Pattnaik, A. K. ( 2006; ). Insertion and deletion analyses identify regions of non-structural protein 5A of Hepatitis C virus that are dispensable for viral genome replication. J Gen Virol 87, 323–327.[CrossRef]
    [Google Scholar]
  30. Maertens, G. S. L. ( 1997; ). Genotypes and genetic variation of hepatitis C virus. In The Molecular Medicine of Viral Hepatitis. Edited by T. J. Harrison & A. J. Zuckerman. New York: John Wiley.
  31. Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M. & Albrecht, J. K. ( 2001; ). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958–965.[CrossRef]
    [Google Scholar]
  32. Manzin, A., Solforosi, L., Petrelli, E., Macarri, G., Tosone, G., Piazza, M. & Clementi, M. ( 1998; ). Evolution of hypervariable region 1 of hepatitis C virus in primary infections. J Virol 72, 6271–6276.
    [Google Scholar]
  33. Pawlotsky, J. M. ( 2006; ). Therapy of hepatitis C: from empiricism to eradication. Hepatology 43, S207–S220.[CrossRef]
    [Google Scholar]
  34. Penin, F., Combet, C., Germanidis, G., Frainais, P. O., Deleage, G. & Pawlotsky, J. M. ( 2001; ). Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment. J Virol 75, 5703–5710.[CrossRef]
    [Google Scholar]
  35. Polyak, S. J., Faulkner, G., Carithers, R. L., Jr, Corey, L. & Gretch, D. R. ( 1997; ). Assessment of hepatitis C virus quasispecies heterogeneity by gel shift analysis: correlation with response to interferon therapy. J Infect Dis 175, 1101–1107.[CrossRef]
    [Google Scholar]
  36. Ray, S. C., Wang, Y. M., Laeyendecker, O., Ticehurst, J. R., Villano, S. A. & Thomas, D. L. ( 1999; ). Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. J Virol 73, 2938–2946.
    [Google Scholar]
  37. Reed, K. E. & Rice, C. M. ( 2000; ). Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr Top Microbiol Immunol 242, 55–84.
    [Google Scholar]
  38. Revie, D., Alberti, M. O., Braich, R. S., Bayles, D., Prichard, J. G. & Salahuddin, S. Z. ( 2006; ). Discovery of significant variants containing large deletions in the 5′UTR of human hepatitis C virus (HCV). Virol J 3, 82 [CrossRef]
    [Google Scholar]
  39. Shepard, C. W., Finelli, L. & Alter, M. J. ( 2005; ). Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5, 558–567.[CrossRef]
    [Google Scholar]
  40. Staden, R., Beal, K. F. & Bonfield, J. K. ( 2000; ). The Staden package, 1998. Methods Mol Biol 132, 115–130.
    [Google Scholar]
  41. Thompson, J. D., Gibson, T. J., Plewniak, F., Jeanmougin, F. & Higgins, D. G. ( 1997; ). The clustal_x windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 25, 4876–4882.[CrossRef]
    [Google Scholar]
  42. Torres-Puente, M. ( 2004; ). Variabilidad genética y respuesta al tratamiento antiviral en el virus de la Hepatitis C (VHC). PhD thesis, Universidad de Valencia.
  43. Troesch, M., Meunier, I., Lapierre, P., Lapointe, N., Alvarez, F., Boucher, M. & Soudeyns, H. ( 2006; ). Study of a novel hypervariable region in hepatitis C virus (HCV) E2 envelope glycoprotein. Virology 352, 357–367.[CrossRef]
    [Google Scholar]
  44. Vallet, S., Gouriou, S., Nkontchou, G., Hotta, H., Vilerio, M., Legrand-Quillien, M. C., Beaugrand, M., Trinchet, J. C., Nousbaum, J. B. & other authors ( 2007; ). Is hepatitis C virus NS3 protease quasispecies heterogeneity predictive of progression from cirrhosis to hepatocellular carcinoma? J Viral Hepat 14, 96–106.[CrossRef]
    [Google Scholar]
  45. Wasley, A. & Alter, M. J. ( 2000; ). Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 20, 1–16.[CrossRef]
    [Google Scholar]
  46. Weiner, A. J., Brauer, M. J., Rosenblatt, J., Richman, K. H., Tung, J., Crawford, K., Bonino, F., Saracco, G., Choo, Q. L. & Houghton, M. ( 1991; ). Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 180, 842–848.[CrossRef]
    [Google Scholar]
  47. Yagnik, A. T., Lahm, A., Meola, A., Roccasecca, R. M., Ercole, B. B., Nicosia, A. & Tramontano, A. ( 2000; ). A model for the hepatitis C virus envelope glycoprotein E2. Proteins 40, 355–366.[CrossRef]
    [Google Scholar]
  48. Zekri, A. R., El Din, H. M., Bahnassy, A. A., Khaled, M. M., Omar, A., Fouad, I., El Hefnewi, M., Thakeb, F. & El Awady, M. ( 2007; ). Genetic distance and heterogeneity between quasispecies is a critical predictor to IFN response in Egyptian patients with HCV genotype-4. Virol J 4, 16 [CrossRef]
    [Google Scholar]
  49. Zhang, J., Yamada, O., Ito, T., Akiyama, M., Hashimoto, Y., Yoshida, H., Makino, R., Masago, A., Uemura, H. & Araki, H. ( 1999; ). A single nucleotide insertion in the 5′-untranslated region of hepatitis C virus leads to enhanced cap-independent translation. Virology 261, 263–270.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.82855-0
Loading
/content/journal/jgv/10.1099/vir.0.82855-0
Loading

Data & Media loading...

Supplements

vol. , part 8, pp. 2198 - 2203

Main features of, and number of viral clones sequenced from patients infected with HCV subtype 1a included in this study

Main features of, and number of viral clones sequenced from patients infected with HCV subtype 1b included in this study

Patients with insertions in the E1–E2 region [Single PDF file](79 KB)



PDF

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error